雖然這篇SOLOIST-WHF鄉民發文沒有被收入到精華區:在SOLOIST-WHF這個話題中,我們另外找到其它相關的精選爆讚文章
[爆卦]SOLOIST-WHF是什麼?優點缺點精華區懶人包
你可能也想看看
搜尋相關網站
-
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#1Effect of Sotagliflozin on Cardiovascular Events in Patients ...
SOLOIST -WHF is the first large randomized controlled trial to show that initiation of SGLT2 inhibition in acute HF in stabilized patients prior ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#2Sotagliflozin in Patients with Diabetes and Recent ... - PubMed
SOLOIST -WHF Trial Investigators: Deepak L Bhatt, Christopher P Cannon, Lawrence A Leiter, Julia B Lewis, Darren K McGuire, Bertram Pitt, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#3Effect of Sotagliflozin on Cardiovascular ... - ClinicalTrials.gov
Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial) ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#4SOLOIST‐WHF and updated meta‐analysis: sodium–glucose ...
In summary, SOLOIST-WHF contributes three very important findings relevant to the use of SGLT2 inhibitors in clinical practice. First, it adds a ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#5SOLOIST-WHF: Sotagliflozin in patients with diabetes and ...
Significant increases in: Diarrhea: 6.1% vs 3.4%. Severe hypoglycemia: 1.5% vs 0.3% · No significant differences in: Serious adverse events ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#6#CardsJC: SOLOIST-WHF Trial Journal Club - Cardionerds
86 events/100 patient-years (p = 0.003) ... SOLOIST-WHF trial showed that Sotagliflozin (a nonspecific SGLTi) significantly reduced the rates of ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#7results of the SOLOIST-WHF trial - Taylor & Francis Online
The results of the SOLOIST-WHF trial demonstrate that Sotagliflozin may serve as an advantageous option for patients who need glycemic control and who have ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#8(PDF) SOLOIST-WHF: Sodium-glucose cotransporter 2 ...
PDF | On Dec 6, 2020, Kieran F. Docherty and others published SOLOIST-WHF: Sodium-glucose cotransporter 2 (SGLT2) inhibitors should be initiated in patients ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#9Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials
In the SOLOIST-WHF study, which was prematurely stopped after losing funding from the study sponsor amid the ongoing COVID-19 pandemic, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#10The Pooled SCORED and SOLOIST-WHF Analysis
The SCORED and SOLOIST-WHF trials showed a beneficial effect of sotagliflozin (a sodium-glucose cotransporter [SGLT]-1 and -2 inhibitor) on ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#11SOLOIST-WHF - Healio
2021年2月18日 — SOLOIST-WHF ... Sotagliflozin (Zynquista, Lexicon/Sanofi) vs. placebo in patients with type 2 diabetes recently hospitalized for worsening HF.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#12SOLOIST-WHF | ACROSS HF - Boehringer Ingelheim
Welcome to ACROSS Heart Failure. Access the unique heart failure resources developed in collaboration with our esteemed steering committee.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#13Effect of Sotagliflozin on Total Hospitalizations ... - ACP Journals
In the SOLOIST-WHF (Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure) trial, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#14Sotagliflozin 和失代偿性心力衰竭:SOLOIST-WHF 试验的结果
(2021). Sotagliflozin and decompensated heart failure: results of the SOLOIST-WHF trial. Expert Review of Clinical Pharmacology: Vol.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#15SOLOIST-WHF (Completed) - wcn.life
SOLOIST -WHF (Completed). A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of SOtagLiflozin on ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#16SOLOIST-WHF: Sotagliflozin beneficial when started shortly ...
SOLOIST -WHF: Sotagliflozin given directly after an acute heart failure episode reduces the risk for further cardiovascular events in people ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#17Sotagliflozin in Patients with Diabetes and ... - Semantic Scholar
Worsening Heart Failure – The SOLOIST-WHF Trial. Deepak L. Bhatt, MD, MPH, Michael Szarek, PhD, Ph. Gabriel Steg, MD,. Christopher P. Cannon, MD, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#18Clinical Research Trial Listing ( Heart Failure-Type 2 Diabetes ...
... 2 Diabetes Mellitus , Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#19Sotagliflozin, the cardiovascular and renal benefits
Two recent clinical studies, SCORE and SOLOIST-WHF, explored the renal and cardiovascular benefit of sotagliflozin in participants with type ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#20Dr. Deepak Bhatt and Dr. C. Michael Gibson Discuss - Clinical ...
Dr. Deepak Bhatt and Dr. C. Michael Gibson Discuss: The SOLOIST-WHF and SCORED Trials: Sotagliflozin in Diabetes Patients. Search for:
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#21SOLOIST‐WHF and updated meta‐analysis - University of ...
SOLOIST -WHF and updated meta-analysis: sodium–glucose co-transporter 2 inhibitors should be initiated in patients hospitalized with worsening heart failure.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#22Modified research protocol breaks our heart a little in an ...
Modified research protocol breaks our heart a little in an otherwise handsome trial of sotagliflozin (SOLOIST-WHF). EBM Focus - Volume 16, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#23Addendum. 10. Cardiovascular Disease and Risk Management
tes Post Worsening Heart Failure (SOLOIST-WHF). The online version of the article (https://doi.org/10.2337/dc21-S010) reflects the changes described below.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#24sotagliflozin reduces total hospitalizations and increases days ...
SOTAGLIFLOZIN REDUCES TOTAL HOSPITALIZATIONS AND INCREASES DAYS ALIVE AND OUT OF HOSPITAL IN THE SOLOIST-WHF TRIAL · Michael Szarek · Deepak Bhatt ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#25American College of Cardiology on Twitter: "The SOLOIST ...
The SOLOIST-WHF trial showed that sotagliflozin has salutary effects on cardiovascular outcomes among patients with type 2 #Diabetes mellitus and recent ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#26Sotagliflozin Shows Promise in Diabetic Patients with ...
Findings from the SOLOIST-WHF trial demonstrated that sotagliflozin can lead to reduced cardiovascular-related deaths, hospitalizations, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#27Episode 127: The SOLOIST-WHF and SCORED Trials
Play Episode 127: The SOLOIST-WHF and SCORED Trials by Talking Points on desktop and mobile. Play over 265 million tracks for free on ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#28Association of Sodium-Glucose Cotransporter 2 Inhibitors With ...
A recently published trial, SOLOIST-WHF, studied the cardiovascular outcomes in patients with worsening of existing heart failure requiring ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#29Sotagliflozin shows signal in heart failure with preserved ...
Sotagliflozin Findings Suggest Benefit for Hard-to-Treat HF Population · A Unique Mechanism of Action · Results for SOLOIST-WHF.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#30Researchers will provide new data from SCORED and ...
... Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF) trials were published in the New England Journal of Medicine in January 2021.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#31Diabetes Distilled: Effects of sotagliflozin in people with type 2 ...
The SCORED and SOLOIST-WHF trials of the dual sodium–glucose cotransporter 1/2 (SGLT1/2) inhibitor sotagliflozin were both presented at the ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#32配合中央流行疫情指揮中心{防疫新生活運動}要將下列五項
另一個可能推廣到SGLT2抑製劑的發現,源於SOLOIST-WHF的設計,該設計測. 試了在急性心臟衰竭失代償住院後,穩定的第2 型糖尿病患者開始服用.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#33Effect of Sotagliflozin on Cardiovascular ... - Cochrane Library
Effect of Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabètes Post Worsening Heart Failure (SOLOIST-WHF Trial). EUCTR2017‐003510‐16‐SK.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#34Revisión de artículos: Estudios relevantes presentados en el ...
El estudio SOLOIST-WHF evaluó si sotagliflozina prevenía muerte cardiovascular y hospitalizaciones o visitas urgentes por insuficiencia ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#35ICTRP Search Portal - WHO | World Health Organization
... Effect of Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabètes Post Worsening Heart Failure (SOLOIST-WHF Trial).
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#36Is Dual Inhibition the Cherry on the Cake of Cardiorenal ...
In SOLOIST-WHF, sotagliflozin reduced the risk of the primary composite outcome of cardiovascular (CV) death and hospitalizations and urgent ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#37Dual SGLT1 and SGLT2 inhibitor reduces CV outcomes in ...
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure – The SOLOIST-WHF trial. Sotagliflozin in patients with diabetes ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#38a systematic review and meta-analysis of randomized trials
In SOLOIST-WHF, there were no data regarding NYHA class at baseline presented. DAPA-HF and EMPEROR-Reduced included ambulatory patients with ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#39Dr. Bhatt LBS7 SCORED and SOLOIST-WHF - American ...
... SCORED and SOLOIST-WHF, during an embargoed, virtual media briefing at the American Heart Association Scientific Sessions 2020.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#40Gliflozins for the prevention of stroke in diabetes and card...
The SOLOIST-WHF trial adds the more evidence of gliflozins used in the subgroup of T2D patients with HF, the SCORED trial adds that of ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#41Women and Diabetes: Preventing Heart Disease in a New Era ...
SOLOIST -WHF was the first RCT in the history of cardiology to demonstrate a significant reduction of major combined endpoints such as total HHF + CV death + ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#42The Future of Sotagliflozin With Deepak Bhatt, MD - Practical ...
A dual SGLT1/2 inhibitor, sotagliflozin made a splash in late 2020 with the SOLOIST-WHF and SCORED trials, which demonstrated the agent ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#43SOLOIST-WHF Trial - Slideshare
SOLOIST -WHF Trial CRITERIOS DE INCLUSIÓN Luna Carrillo Alemán Bhatt presentation, AHA 2020 Ingreso con síntomas y signos de Insuficiencia ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#44ESC Heart Failure; 7(6):3261-3267, 2020. | ProQuest Central
Early initiation of SGLT2 inhibitors is important, irrespective of ejection fraction: SOLOIST‐WHF in perspective. Verma, Subodh, Anker, Stefan D.; Butler, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#45SOLOIST WHF & SCORED - Sociedad Interamericana de ...
SOLOIST WHF & SCORED. Beneficios de la inhibición SGLT1/2 con sotagliflozina en Insuficiencia cardíaca y fracción de eyección preservada.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#46Q64150623 - Wikidata
Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial) · Statements.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#47mmc1.pdf - The Lancet
for heart failure (i.e. SOLOIST-WHF). Standard errors (SE) in the ... kidney disease progression unavailable for SOLOIST-WHF. EMPA-REG OUTCOME population ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#48Kofam | Studienregister SNCTP
Effect of Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabètes Post Worsening Heart Failure (SOLOIST-WHF Trial).
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#49Thai Heart - SOLOIST-WHF The SOLOIST-WHF trial showed...
SOLOIST -WHF The SOLOIST-WHF trial showed that sotagliflozin has salutary effects on CV outcomes among patients with T2DM and HF.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#50SGLT2 inhibitors and the risk of urinary tract infections in ...
most recent SOLOIST-WHF [7] trial demonstrated a 33% relative risk reduction in the total number of deaths from cardiovascular causes and ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#51NEJM医学前沿
SOLOIST -WHF试验表明,在心力衰竭恶化的糖尿病患者中,SGLT2和SGLT1抑制剂sotagliflozin组的主要终点(心血管原因死亡及因心力衰竭住院和紧急就诊的总数) ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#522020 Top Stories in Cardiology: SOLOIST and SCORED
The SOLOIST trial studied sotagliflozin versus placebo in type 2 ... With Type 2 Diabetes Post Worsening Heart Failure - SOLOIST-WHF.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#53Does SGLT1 Inhibition Add Benefit to SGLT2 ... - AHA Journals
The results of SOLOIST and SCORED suggest that additional SGLT1 inhibition ... Voors AA, Metra M, et al. ; SOLOIST-WHF Trial Investigators.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#54Sotagliflozin reduces overall hospital time for people with ...
... the amount of time people with type 2 diabetes and heart failure are alive and not in hospital, shows further analysis of SOLOIST-WHF.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#55SGLT-2 inhibitors - Repositório da Universidade de Lisboa
The SOLOIST WHF: A SGTL-2 and SGLT1 inhibitor random- ized trial in patients with type 2 diabetes and recent worsening heart failure.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#56SOLOIST by lauracpenam on Genially
Discover more about SOLOIST ✌️ - Presentation. ... SOLOIST WHF. Sotagliflozina en pacientes con diabetes y ... SOLOIST. lauracpenam. Created on 18/11/2020.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#57Late breaking science presented at AHA 2020 - European ...
SOLOIST -WHF trial. Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure or death from cardiovascular (CV) ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#58ADA 2021: Pooled data from SOLOIST-WHF and SCORED ...
ADA 2021: Pooled data from SOLOIST-WHF and SCORED establishes efficacy of sotagliflozin.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#59SGLT-2 inhibitors: A step forward in the treatment of heart ...
The recently published SOLOIST WHF in patients with T2D and recent worsening HF showed that sotagliflozin – a SGTL-2 and SGLT1 inhibitor – versus placebo, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#60SOLOIST-WHF és SOLDER - Magyar Diabetes Társaság
A New Engl J Med hasábjain egy számban jelentek meg a SOLOIST-WHF és a SOLDER vizsgálat eredményei. Mindkét vizsgálatot az SGLT2/SGLT1 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#61Cardiovascular Outcome in Patients Treated With SGLT2 ...
Our meta-analysis included three large clinical trials, which were performed only in HF participants: DAPA-HF, EMPEROR-Reduced, and SOLOIST-WHF ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#62SGLT-2 inhibitors and cardiorenal outcomes in patients with or ...
SOLOIST -WHF compared sotagliflozin to placebo in 1222 patients with T2D who were recently hospitalized for worsening heart failure [23]. EMPEROR ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#63More Positive Results for Zynquista - Managed Healthcare ...
The SOLOIST-WHF trial enrolled just over 1,200 patients with type 2 diabetes who had been hospitalized recently for worsening heart failure.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#64Sodium-glucose Co-transporter 2 Inhibitors - KoreaMed ...
The SOLOIST-WHF was the latest outcome trial to assess the effect of SGLT2i, sotagliflozin in HFrEF patients with diabetes who were recently ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#65ACC: Is SGLT Inhibition the Real Deal in HFpEF? - Physician's ...
Taken together, the SCORED and SOLOIST-WHF trials not only presented the full-spectrum of heart failure, from HFrEF to HFpEF, but also looked at ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#66First SGLT1/2 inhibitor shows 'spectacular' phase 3 safety and ...
SOLOIST -WHF enrolled patients hospitalized for worsening heart failure who also required intravenous diuretic treatment but had become stable ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#67Sotagliflozin Prevents Heart Events in Acute HF, Chronic ...
Almost 21% of SOLOIST-WHF participants had heart failure with preserved ejection fraction (HFpEF), and the benefit of sotagliflozin appeared ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#68SOLOIST-WHF and SCORED Results - CPR and More LLC
Hello, I'm Dr. Deepak Bhatt. And it is really a pleasure for me to provide a quick recap of the soloist and scored late breaking clinical ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#69Pre-/post-discharge sotagliflozin may reduce CV death - MIMS ...
“The results of the SOLOIST-WHF trial clearly support the rationale for the use of sotagliflozin – and perhaps other SGLT2 inhibitors – in ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#70Effect of Sotagliflozin on Total Hospitalizations in Patients With ...
SOLOIST -WHF committees and investigators, Veli-Pekka Harjola · HUS Emergency Medicine and Services. Research output: Contribution to journal ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#71Sotagliflozin for Diabetes Patients with Worsening Heart ...
In the SOLOIST-WHF study, 1222 patients (from 306 sites in 32 countries) with diabetes and HF with reduced or preserved ejection fraction ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#72Acute kidney injury with sodium-glucose co-transporter-2 ...
... Who Are at Cardiovascular Risk (SCORED) trial and the Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure (SOLOIST-WHF) trial.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#73SCORED, SOLOIST Trials to Add to Evidence for Treating ...
In the “The Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure” (SOLOIST-WHF) ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#74Clinical Research Trials - Monument Health
SOLOIST -WHF. Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart. Failure.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#75항당뇨병제 진퀴스타, '콩팥병'·'심부전' 환자 겨냥 - 메디칼업저버
SOLOIST -WHF, 심부전 악화 환자 퇴원전·후 치료 시 심혈관질환 사망·심부전 입원 등 위험↓. [메디칼업저버 박선혜 기자] SGLT-1과 SGLT-2를 동시에 억제 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#76SGLT-2 inhibitors in heart failure: Time for broader eligibility ...
SOLOIST -WHF trial: More evidence. The clinical trial Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#77Are post-hoc analyses on subgroups sufficient to support new ...
Similarly, in the SOLOIST-WHF (Effect of Sotagliflozin on Cardiovascular. Events in Patients with Type 2 Diabetes Post Worsening Heart ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#78Sotagliflozin in Patients with Diabetes and Recent Worsening ...
(Funded by Sanofi and Lexicon Pharmaceuticals; SOLOIST-WHF ClinicalTrials.gov number, .) Original language, English. Pages (from-to), 117-128.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#79Sotagliflozin's HFpEF benefit confirmed by new analyses - The ...
Researchers who ran the SCORED and SOLOIST-WHF pivotal trials for sotagliflozin first made that claim in November 2020 when reporting ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#80SOLOIST-WHF démontre les bénéfices de la sotagliflozine ...
SOLOIST -WHF démontre les bénéfices de la sotagliflozine dans l'insuffisance cardiaque aiguë du patient diabétique. Patrice DARMON, Marseille.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#81Sotagliflozin shows benefit for difficult-to-treat form of heart ...
2021年5月17日 — The SOLOIST-WHF trial evaluated whether sotagliflozin prevented cardiovascular deaths and hospitalizations or urgent visits for heart ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#82第五個SGLT2抑制劑Sotagliflozin的心血管報告出來但是帶有遺憾
SOLOIST -WHF針對因為心衰竭住院的第二型糖尿病患者,在生命跡象穩定後,在住院中或是剛出院時給予Sotagliflozin,觀察心血管死亡或是心衰竭住院的風險。
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#83《NEJM》SGLT1/2雙重抑制劑糖尿病藥首見降低糖尿病患者中風
另一項試驗稱為SOLOIST-WHF,納入18至85歲因心衰竭住院並接受利尿劑治療的糖尿病患者共1222名,隨機分為608名受試者接受sotagliflozin治療,614名受試 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#84Sotagliflozin Makes Waves at AHA 2020 with Phase 3 ...
SOLOIST -WHF was designed as a multicenter, double-blind trial of patients with type 2 diabetes who were recently hospitalized for worsening ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#85EU Clinical Trials Register
Diabètes Post Worsening Heart Failure (SOLOIST-WHF Trial). Επίδραση του sotagliflozin σουταγλιφλοζίνης σε καρδιαγγειακά συμβάματα σε ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#86Sotagliflozin reduces adverse cardiovascular events - Nature
Similarly, in the SOLOIST-WHF trial, 1,222 patients with T2DM who were recently hospitalized for worsening heart failure were randomly ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#87「Sotagliflozinは心不全治療薬」仮説を生成:SOLOIST-WHF
【背景】 SGLT1/2阻害薬sotagliflozinは、現在EMAがT2D薬として承認している。Brigham and Women's HospitalのBhattら(SOLOIST-WHF)は、急性(非 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#88Diabetes Distilled Effects of sotagliflozin in people with type 2 ...
SOLOIST -WHF aimed to assess the safety and efficacy of sotagliflozin initiated soon after an episode of decompensated heart failure (HF) in ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#89Herzinsuffizienz: SGLT2-Hemmer verbessert Prognose
In der randomisierten doppelblinden SOLOIST-WHF-Studie konnte mit Sotagliflozin die Inzidenz von kardiovaskulären Todesfällen und ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#90Top 5 Takeaways on SGLT2 Inhibitors From AHA 2020
Sotagliflozin in diabetes patients with recent worsening heart failure--SOLOIST-WHF. Presented at: American Heart Association 2020 Virtual ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#91M 2 failure. Diabetes Obes Metab. Normal EF is 55-60%. 2 ...
2 is a Crucial P. b. , on behalf of the SOLOIST-WHF Committees and Investigators. Original Mars & Mars C only supports printing the file in ".
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#92Sotagliflozin, inibitore SGLT1 e SGLT2: meno ricoveri per ...
Gli studi SCORED e SOLOIST-WHF, entrambi presentati al meeting virtuale dell American Heart Association 2020 e pubblicati contemporaneamente ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#93Nephrocardiology, An Issue of Cardiology Clinics, E-Book
... WHF trial (discussed earlier), a prespecified subgroup analysis suggested a ... This finding was confirmed in a pooled analysis of SOLOIST and SCORED.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#94The ESC Textbook of Intensive and Acute Cardiovascular Care
SIRS SLEDD SMUR SNF SNP SOAP RR RRT RSCD rSO2 RT rtPA RT- PCR RV RVAD RVEF RVOT RWPT SOAP II SOD SOFA s SOLOIST- WHF S1P SPC SPECT SAH SALT SaO2 SAPS SAT ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?>
soloist-whf 在 コバにゃんチャンネル Youtube 的最佳解答
soloist-whf 在 大象中醫 Youtube 的最佳貼文
soloist-whf 在 大象中醫 Youtube 的最佳貼文